Paper35682802
New Developments in Carbonic Anhydrase IX-Targeted Fluorescence and Nuclear Imaging Agents.
Chen KT and 1 other. Int J Mol Sci, 2022. Cited by 23 papers, by iCite.
Cite this record
ConductScience Library. New Developments in Carbonic Anhydrase IX-Targeted Fluorescence and Nuclear Imaging Agents. Papers, record 35682802. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35682802
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- New Developments in Carbonic Anhydrase IX-Targeted Fluorescence and Nuclear Imaging Agents.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antigens, Neoplasm | Major topic |
| Neoplasms | Major topic |
| Animals | |
| Antibodies, Monoclonal | |
| Carbonic Anhydrase IX | |
| Mice | |
| Mice, Nude | |
| Positron-Emission Tomography |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| MOST110-2113-M-259-001-MY2 | Ministry of Science and Technology, Taiwan | PubMed |
Source PubMed
References73
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33651116 | Phase I study to assess safety, biodistribution and radiation dosimetry for 89Zr-girentuximab in patients with renal cell carcinoma. | Eur J Nucl Med Mol Imaging | 2021 | https://conductscience.org/library/papers/33651116 | PubMed |
| 2 | 22145736 | Dithiocarbamates strongly inhibit the β-class carbonic anhydrases from Mycobacterium tuberculosis. | J Enzyme Inhib Med Chem | 2013 | https://conductscience.org/library/papers/22145736 | PubMed |
| 3 | 30550290 | Quantitative Imaging of the Hypoxia-Related Marker CAIX in Head and Neck Squamous Cell Carcinoma Xenograft Models. | Mol Pharm | 2019 | https://conductscience.org/library/papers/30550290 | PubMed |
| 4 | 33576099 | Process validation, current good manufacturing practice production, dosimetry, and toxicity studies of the carbonic anhydrase IX imaging agent [111 In]In-XYIMSR-01 for phase I regulatory approval. | J Labelled Comp Radiopharm | 2021 | https://conductscience.org/library/papers/33576099 | PubMed |
| 5 | 31827111 | CAIX-targeting radiotracers for hypoxia imaging in head and neck cancer models. | Sci Rep | 2019 | https://conductscience.org/library/papers/31827111 | PubMed |
| 6 | 27362480 | Evaluation of Nonpeptidic Ligand Conjugates for SPECT Imaging of Hypoxic and Carbonic Anhydrase IX-Expressing Cancers. | Bioconjug Chem | 2016 | https://conductscience.org/library/papers/27362480 | PubMed |
| 7 | 34485720 | Imaging carbonic anhydrase IX as a method for monitoring hypoxia-related radioresistance in preclinical head and neck cancer models. | Phys Imaging Radiat Oncol | 2021 | https://conductscience.org/library/papers/34485720 | PubMed |
| 8 | 26866675 | PET Imaging of Carbonic Anhydrase IX Expression of HT-29 Tumor Xenograft Mice with (68)Ga-Labeled Benzenesulfonamides. | Mol Pharm | 2016 | https://conductscience.org/library/papers/26866675 | PubMed |
| 9 | 20359812 | Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. | Eur Urol | 2010 | https://conductscience.org/library/papers/20359812 | PubMed |
| 10 | 20610160 | Synthesis and biological evaluation of a 99mTc-labelled sulfonamide conjugate for in vivo visualization of carbonic anhydrase IX expression in tumor hypoxia. | Nucl Med Biol | 2010 | https://conductscience.org/library/papers/20610160 | PubMed |
| 11 | 30577607 | A Flexible Synthesis of 68Ga-Labeled Carbonic Anhydrase IX (CAIX)-Targeted Molecules via CBT/1,2-Aminothiol Click Reaction. | Molecules | 2018 | https://conductscience.org/library/papers/30577607 | PubMed |
| 12 | 33472371 | Modulation of the Pharmacokinetics of a Radioligand Targeting Carbonic Anhydrase-IX with Albumin-Binding Moieties. | Mol Pharm | 2021 | https://conductscience.org/library/papers/33472371 | PubMed |
| 13 | 22079760 | Synthesis and evaluation of near-infrared fluorescent sulfonamide derivatives for imaging of hypoxia-induced carbonic anhydrase IX expression in tumors. | Bioorg Med Chem Lett | 2012 | https://conductscience.org/library/papers/22079760 | PubMed |
| 14 | 29778927 | Evaluation of 99mTc-sulfonamide and sulfocoumarin derivatives for imaging carbonic anhydrase IX expression. | J Inorg Biochem | 2018 | https://conductscience.org/library/papers/29778927 | PubMed |
| 15 | 23463940 | Synthesis and evaluation of 18F-labeled carbonic anhydrase IX inhibitors for imaging with positron emission tomography. | J Enzyme Inhib Med Chem | 2014 | https://conductscience.org/library/papers/23463940 | PubMed |
| 16 | 18242985 | Carbonic anhydrase inhibitors: interactions of phenols with the 12 catalytically active mammalian isoforms (CA I-XIV). | Bioorg Med Chem Lett | 2008 | https://conductscience.org/library/papers/18242985 | PubMed |
| 17 | 30803240 | Targeting CAIX with [64Cu]XYIMSR-06 Small Molecular Radiotracer Enables Noninvasive PET Imaging of Malignant Glioma in U87 MG Tumor Cell Xenograft Mice. | Mol Pharm | 2019 | https://conductscience.org/library/papers/30803240 | PubMed |
| 18 | 33011287 | Synthesis and evaluation of novel technetium-99m-hydroxamamide complex based on imidazothiadiazole sulfonamide targeting carbonic anhydrase-IX for tumor imaging. | Bioorg Med Chem Lett | 2020 | https://conductscience.org/library/papers/33011287 | PubMed |
| 19 | 23213092 | Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. | J Clin Oncol | 2013 | https://conductscience.org/library/papers/23213092 | PubMed |
| 20 | 23226406 | In vivo imaging and quantification of carbonic anhydrase IX expression as an endogenous biomarker of tumor hypoxia. | PLoS One | 2012 | https://conductscience.org/library/papers/23226406 | PubMed |
Cited by16
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 23 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42653817 | Explainable Multi-Isoform QSAR, PubChem Concordance, and Applicability-Domain-Guided Prioritization of Selective Human Carbonic Anhydrase I, II, IX, and XII Inhibitors. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42653817 | PubMed |
| 41799189 | CAIX-targeted α therapy directed against hypoxic tumor cells in combination with immune checkpoint inhibitors in a syngeneic mouse tumor model. | Theranostics | 2026 | https://conductscience.org/library/papers/41799189 | PubMed |
| 41754999 | 89Zr-girentuximab PET/CT Enables Noninvasive Assessment of Indeterminate Renal Masses and Metastatic Clear-Cell Renal Cell Carcinoma. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/41754999 | PubMed |
| 41631002 | Carbonic Anhydrase-IX Is a Specific and Sensitive Theragnostic Target for Imaging and Radioimmunotherapy in Metastatic Colorectal Cancer. | Gastro Hep Adv | 2026 | https://conductscience.org/library/papers/41631002 | PubMed |
| 41498693 | Oral Administration of a Bivalent Carbonic Anhydrase IX Near-Infrared Imaging Agent Detects Hypoxic Tumors in a Mouse Model. | ACS Sens | 2026 | https://conductscience.org/library/papers/41498693 | PubMed |
| 41251718 | AXINEO: AXIllary response to NEOadjuvant chemotherapy for breast cancer: can we predict response based on a biomarker panel? | Arch Gynecol Obstet | 2025 | https://conductscience.org/library/papers/41251718 | PubMed |
| 41067863 | SNMMI/EANM/ACNM Procedure Standard/Procedure Guideline on the Use of Molecular Imaging for Renal Mass Characterization. | J Nucl Med | 2025 | https://conductscience.org/library/papers/41067863 | PubMed |
| 40860130 | Imaging hypoxia for head and neck cancer: current status, challenges, and prospects. | Theranostics | 2025 | https://conductscience.org/library/papers/40860130 | PubMed |
| 40831613 | Novel radiopharmaceuticals for molecular imaging of renal cell carcinoma. | BMJ Oncol | 2025 | https://conductscience.org/library/papers/40831613 | PubMed |
| 39740867 | Correlation of Preclinical In Vivo Imaging Modalities and Immunohistochemistry for Tumor Hypoxia and Vasculature. | In Vivo | 2025 | https://conductscience.org/library/papers/39740867 | PubMed |
| 39543358 | Molecular imaging of renal cell carcinomas: ready for prime time. | Nat Rev Urol | 2025 | https://conductscience.org/library/papers/39543358 | PubMed |
| 39361163 | Tumor hypoxia unveiled: insights into microenvironment, detection tools and emerging therapies. | Clin Exp Med | 2024 | https://conductscience.org/library/papers/39361163 | PubMed |
| 39091919 | Tumor perfusion enhancement by microbubbles ultrasonic cavitation reduces tumor glycolysis metabolism and alleviate tumor acidosis. | Front Oncol | 2024 | https://conductscience.org/library/papers/39091919 | PubMed |
| 38750635 | High-Affinity NIR-Fluorescent Inhibitors for Tumor Imaging via Carbonic Anhydrase IX. | Bioconjug Chem | 2024 | https://conductscience.org/library/papers/38750635 | PubMed |
| 38473402 | Monoclonal Antibodies for Targeted Fluorescence-Guided Surgery: A Review of Applicability across Multiple Solid Tumors. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38473402 | PubMed |
| 36982946 | Progress of Section "Biochemistry" in 2022. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/36982946 | PubMed |
Genes9
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ALB | 213 | PubTator's text mining | https://conductscience.org/library/genes/213 | NCBI Gene |
| CA2 | 760 | PubTator's text mining | https://conductscience.org/library/genes/760 | NCBI Gene |
| CA9 | 768 | PubTator's text mining | https://conductscience.org/library/genes/768 | NCBI Gene |
| GCG | 2641 | PubTator's text mining | https://conductscience.org/library/genes/2641 | NCBI Gene |
| GRP | 2922 | PubTator's text mining | https://conductscience.org/library/genes/2922 | NCBI Gene |
| HIF1A | 3091 | PubTator's text mining | https://conductscience.org/library/genes/3091 | NCBI Gene |
| NPY | 4852 | PubTator's text mining | https://conductscience.org/library/genes/4852 | NCBI Gene |
| USH2A | 7399 | PubTator's text mining | https://conductscience.org/library/genes/7399 | NCBI Gene |
| VHL | 7428 | PubTator's text mining | https://conductscience.org/library/genes/7428 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35682802
GET https://conductscience.org/api/papers/v1/35682802/references?page=2